Pharmaceutical Nanotechnology and Nanomedicine

Biography

Biography: Arkesh Mehta

Abstract

While major progress has been achieved in research and development, the majority of new therapies continue to fail in human trials, despite showing promise in preclinical testing. As the Big Pharma model of producing a drug from soup to nuts has proven to be less effective at getting novel drugs to market, the drug discovery and development process have become fragmented. Additionally, as the science and regulatory requirements get more complex there is a need for more depth of expertise in each of these segments, which plays to the strengths of innovative companies. The years- to decades-long process can be complex, and there is nearly always a moment of uncertainty that a drug will succeed in the next phase of development. This long development pipeline faces increasing costs and additional challenges, including the lack of predictive validity of current animal models, insufficient knowledge regarding underlying mechanisms of disease, patient heterogeneity, lack of targets and biomarkers, a high rate of failed clinical trials, and regulatory challenges. To better understand how these challenges, create bottlenecks in the development pipeline, a cost-efficient and unified drug development architecture are critical for the success of sustainable biopharma companies.

This presentation introduces Aayush Biosphere’s Hyperscale™ Technology and the two ways it may be implemented: (a) Aayush BioSphere NanoBindi™ technology is a scale-out infrastructure based on the Patient's clinical preferences. (b) Aayush BioSphere NanoBindi™ technology is a clinical outcome focused solution that tightly integrates drug API (s), cell-specific targeting, on demand controlled release and full lifecycle management and analytics into a single platform across the precision therapeutic development. Built on Avanti Therapeutic's industry-leading technology, it allows Biopharma companies to significantly decrease complexity and cost while increasing both scalability and product pipeline agility.